One sign of the difficulties ahead could come from Eli Lilly's decision to abandon a filing in psoriasis for its IL-23 drug mirikizumab – despite also besting Cosentyx in testing – on the ...

The BE RADIANT trial pitted bimekizumab against Novartis’ Cosentyx (secukinumab) in the treatment of adults with moderate-to-severe psoriasis, and according to UCB is the first study to compare ...

If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.

Jan. 20, 2025 — People with the skin condition psoriasis often have invisible inflammation in the small intestine with an increased propensity for 'leaky gut', according to new research.

During his presentation at the J.P. Morgan Healthcare Conference last week, Incyte CEO Hervé Hoppenot took investors on a ...